19.88

1.64% 0.32

After Hours: 19.55 -0.33 -1.66%

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $19.88, with a volume of 966.15K. It is up +1.64% in the last 24 hours and down -1.83% over the past month. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Previous Close:

$19.56

Open:

$19.46

24h Volume:

966.15K

Relative Volume:

1.00

Market Cap:

$2.33B

Revenue:

$434.48M

Net Income/Loss:

$68.15M

P/E Ratio:

19.68

EPS:

1.01

Net Cash Flow:

$114.96M

1W Performance:

-2.98%

1M Performance:

-1.83%

6M Performance:

+24.72%

1Y Performance:

+70.06%

1-Day Range:

$19.35

$19.91

1-Week Range:

$19.35

$20.80

52-Week Range:

$11.55

$21.66

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1203)

Industry

Biotechnology (681)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

167

Twitter

@CatalystForRare

Next Earnings Date

2024-08-07

Latest SEC Filings

CPRX's Discussions on Twitter

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

04:09 AM

Dimensional Fund Advisors LP Acquires 263,099 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

04:09 AM

Sep 28, 2024

Marshall Wace LLP Trims Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Sep 28, 2024

Sep 27, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 27, 2024

Sep 26, 2024

Profund Advisors LLC Sells 41,182 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Sep 25, 2024

Sep 24, 2024

Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch

Sep 24, 2024

Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade) - Seeking Alpha

Sep 24, 2024

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma - GlobeNewswire

Sep 24, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $29.50 Average Price Target from Brokerages - MarketBeat

Sep 24, 2024

Sep 23, 2024

Integral Health Asset Management LLC Buys Shares of 275,000 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Sep 23, 2024

Pacer Advisors Inc. Has $45.97 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Sep 23, 2024

Sep 20, 2024